Retraction notice to Inhibition of proliferation and induction of apoptosis by 2-benzoyl-3-phenyl-6,7-dichloroquinoxaline 1,4-dioxide in adult T-cell leukemia cells (Chemico-Biological Interactions (2014) 148 (101–113)(S0009279704000493)(10.1016/j.cbi.2004.05.002));Inhibition of proliferation and induction of apoptosis by 2-benzoyl-3-phenyl-6,7-dichloroquinoxaline 1,4-dioxide in adult T-cell leukemia cells

Chemico-Biological Interactions

Volumn 148, Issue 3, 2004, Pages 101-113

  Harakeh, Steve ^a   Diab Assef, Mona ^a   El Sabban, Marwan ^a   Haddadin, Makhluf ^a   Gali Muhtasib, Hala ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Antiproliferation; Apoptosis; ATL cells; Bcl 2 ; Cell cycle arrest; p53

Indexed keywords

2 BENZOYL 3 PHENYL 6,7 DICHLOROQUINOXALINE 1,4 DIOXIDE; ANTIINFECTIVE AGENT; ANTIMITOTIC AGENT; MESSENGER RNA; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; TRANSFORMING GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CYCLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS; LEUKEMIA CELL LINE; PROTEIN EXPRESSION; T CELL LEUKEMIA; UPREGULATION;

HUMAN T-LYMPHOTROPIC VIRUS 1; UNIDENTIFIED RETROVIRUS;

EID: 3342993539     PISSN: 00092797     EISSN: 18727786     Source Type: Journal    
DOI: 10.1016/j.cbi.2017.11.015     Document Type: Erratum

References (47)

1. P.L. Green, I.S.Y. Chen, Molecular features of the human T-cell leukemia virus: mechanisms of transformation and leukemogenicity, in: J.A. Levy (Ed.), The Retroviridae, vol. 3, Plenum Press, New York, 1994, pp. 227-311.
2. Hinuma Y., Komoda H., Chosa T., Kondo T., Kohakura M., Takenaka T., Kikuchi M., Ichimaru M., Yunoki K., Sato I., Matsuo R., Takiuchi Y., Uchino H., Hanaoka M. Antibodies to adult T-cell leukemia-virus-associated antigen (ATLA) in sera from patients with ATL and controls in Japan: a nation-wide sero-epidemiologic study. Int. J. Cancer. 29:1982;631-635
3. Tsukasaki K., Tsuchima H., Yamamura M., Tsukasaki K., Tsushima H., Yamamura M., Hata T., Murata K., Maeda T., Atogami S., Sohda H., Momita S., Ideda S., Katamine S., Yamada Y., Kamihira S., Tomonaga M. Integration patterns of HTLV-I provirus in relation to the clinical course of ATL: frequent clonal change at crisis from indolent disease. Blood. 89:1997;948-956
4. A. Gessain, Epidemiology of HTLV-1 and associated diseases, in: P. Höllsberg, D.A. Hafler (Eds.), Human T-cell Lymphotropic Virus Type 1, Willey, 1996, pp. 33-64.
5. Kaplan J.E., Khabbaz R.F., Murphy E.L., Hermansen S., Roberts C., Lal R., Heneine W., Wright O., Matijas L., Thomson R., Rudolph D., Switzer W.M., Kleinman S., Busch M., Schreiber G.B. Male-to-female transmission of human T-cell lymphotrophic virus types I and II: association with viral load. The retrovirus epidemiology donor study group. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 12:1996;193-201
6. M. Shimoyama, Treatment of patients with adult T-cell leukemia-lymphoma: an overview, in: K. Takatsuki, Y. Hinuma, M. Yoshida, (Eds.), Advances in Adult T-cell Leukemia and HTLV-I Research, vol. 39, Japan Scientific Societies Press, 1992, pp. 43-56.
7. Bazarbachi A., Hermine O. Treatment with a combination of zidovudine and alpha-interferon in naïve and pretreated adult T-cell leukemia/lymphoma patients. J. Acq. Immun. Defic. Synd. Hum. R. 13(Suppl 1):1996;S186-S190
8. Bazarbachi A., El-Sabban M.E., Quignon N.R., Awaragi C., Kersual J., Dianoux L., Zermati Y., Haidar J., Hermine O., De The H. Arsenic trioxide and interferon-α synergize to induce cell cycle arrest and apoptosis in human T-cell lymphatic virus type I-transformed cell. Blood. 93:1999;278-283
9. El-Sabban M.E., Nasr R., Dbaibo G., Hermine O., Abboushi N., Quignon F., Ameisen J.C., Bex F., de The H., Bazarbachi A. Arsenic-interferon-alpha- triggered apoptosis in HTLV-I-transformed cells is associated with tax down-regulation and reversal of NF-kB activation. Blood. 96:2000;2849-2855
10. Hoskin B.D., Lyon P.M. The effect of quindoxin on the growth of broiler chickens. Vet. Rec. 90:1972;396-399
11. Sutter W., Rosselet A., Knusel F. Mode of action of quindoxin and substituted quinoxaline-di-N-oxides on Escherichia coli. Antimicrob. Agents Chemother. 13(6):1978;770-783
12. Carta A., Paglietti G., Rahbar Nikookar M.E., Sanna P., Sechi L., Zanett S. Novel substituted quinoxaline 1,4-dioxides with in vitro antimycobacterial and anticandida activity. Eur. J. Med. Chem. 37:2002;355-366
13. Dirlam J.P., Czuba L.J., Dominy B.W., James R.B., Pezzullo R.M., Presslitz J.E., Windisch W.W. Synthesis and antibacterial activity of 1-hydroxy-1-methyl-1, 3-dihydrofuro [3,4-b] quinoxaline 4,9-dioxide and related compounds. J. Med. Chem. 22:1979;1118-1121
14. Schonfelder D., Stumm G., Bohle M., Niclas H.J. Structure-activity relationships applied to quinoxaline-1,4-dioxides. Pharmazie. 43:1988;837-839
15. Takabatake T., Takabatake Y., Miyazawa T., Hasegawa M. Synthesis and antibacterial properties of quinoxaline 1,4-dioxide derivatives. Yakugaku Zasshi. 116(6):1996;491-496
16. Diab-Assef M., Haddadin M.J., Yared P., Assaad S., Gali-Muhtasib H.U. Quinoxaline 1,4-dioxides: hypoxia-selective therapeutic agents. Mol. Carcinogen. 33:2002;198-205
17. Gali-Muhtasib H.U., Sidani M., Assaf-Diab F.G.M., Haddadin M.J., Zaatari G. Quinoxaline 1,4-dioxides are Novel angiogenesis inhibitors that potentiate antitumor effects of ionizing radiation. Int. J. Oncol. 24:2004;1121-1131
18. Gali-Muhtasib H.U., Haddadin M.J., Rahhal D.N., Younes I. Quinoxaline 1,4-dioxides as anticancer and hypoxia-selective drugs. Oncol. Rep. 8:2001;679-684
19. Foley G.E., Lazarius H., Farber S., Uzman B.G., Boone B.A., McCarthy R.E. Continuous culture of human lymphoblasts from peripheral blood of a child with acute leukemia. Cancer. 10:1965;522-529
20. Haddadin M.J., Issidorides C.H. The Beirut React. Heterocycles. 35:1993;1503-1525
21. Alexandrow M., Moses H. Transforming growth factor β and cell cycle regulation. Cancer Res. 55:1995;1452-1457
22. Wang D., Patil S., Li W., Humphrey L.E., Brattain M.G., Howell G.M. Activation of the TGF-alpha autocrine loop is downstream of IGF-I receptor activation during mitogenesis in growth factor dependent human colon carcinoma cells. Oncogene. 21:2002;2785-2796
23. Wahl S.M. Transforming growth factor beta (TGF-beta) in inflammation: a cause and cure. J. Clin. Immunol. 12:1992;61-74
24. Kehrl J.H., Wakefield L.M., Roberts A.B., Jakowlew S., Alvarez-Mon M., Derynck R., Sporn M.B., Fauci A.S. Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T-cell growth. J. Exp. Med. 163:1986;1037-1050
25. Kanai M., Konda Y., Nakajima T., Izumi Y., Takeuchi T., Chiba T. TGF-alpha inhibits apoptosis of murine gastric pit cells through an NF-kappa-B-dependent pathway. Gastroenterology. 121(1):2001;56-67
26. de Martin R., Haendler B., Hofer-Warbinek R., Gaugitsch H., Wrann M., Schluesener H., Seifert J.M., Bodmer S., Fontana A., Hofer E. Complementary DNA for human glioblastoma-derived T-cell suppressor factor, a novel member of the transforming growth factor-beta gene family. EMBO J. 6:1987;3673
27. Dunker K., Schmitt N., Schuster K., Krieglstein K. The role of transforming growth factor beta-2 beta-3 in mediating apoptosis in the murine intestinal mucosa. Gastroenterology. 122(5):2002;1364-1375
28. Seiki M., Inoue J., Takeda T., Yoshida M. Direct evidence that p40x of human T-cell leukemia virus type I trans-acting transcriptional activator. EMBO J. 5:1986;561-565
29. Brady J., Jeang K.T., Duvall J., Khoury G. Identification of p40x-responsive regulatory sequences within the human T-cell leukemia virus type I long terminal repeat. J. Virol. 61:1987;2175-2181
30. Inoue J., Seiki M., Taniguchi T., Tsuru S., Yoshida M. Induction of interleukin 2 receptor gene expression by p40x encoded by human T-cell leukemia virus type 1. EMBO J. 5:1986;2883-2888
31. Maruyama M., Shibuya H., Harada H., Hatakeyama M., Seiki M., Fujita T., Inoue J., Yoshida M., Taniguchi T. Evidence for aberrant activation of the interleukin-2 autocrine loop by HTLV-1-encoded p40x and T3/Ti complex triggering. Cell. 48:1987;343-350
32. Cross S.L., Feinberg M.B., Wolf J.B., Holbrook N.J., Wong-Staal F., Leonard W.J. Regulation of the human interleukin-2 receptor alpha chain promoter: activation of a nonfunctional promoter by the transactivator gene of HTLV-I. Cell. 49:1987;47-56
33. Siekevitz M., Feinberg M.B., Holbrook N., Wong-Staal F., Greene W.C. Activation of interleukin 2 and interleukin 2 receptor (Tac) promoter expression by the trans-activator (tat) gene product of human T-cell leukemia virus, type I. Proc. Natl. Acad. Sci. U.S.A. 85:1987;5389-5393
34. Fujii M., Sassone-Corsi P., Verma I.M. c-fos Promoter trans-activation by the tax1 protein of human T-cell leukemia virus type I. Proc. Natl. Acad. Sci. U.S.A. 85:1988;8526-8530
35. Wano Y., Feinberg M., Hosking J.B., Bogerg H., Greene W.C. Stable expression of the tax gene of type I human T-cell leukemia virus in human T-cells activates specific cellular genes involved in growth. Proc. Natl. Acad. Sci. U.S.A. 85:1988;9733-9737
36. Nagata K., Ohtani K., Nakamura M., Sagamura K. Activation of endogenous c-fos roto-oncogene expression by human T-cell leukemia virus type I-encoded p40tax protein in the human T-cell line Jurkat. J. Virol. 63:1989;3220-3226
37. Hollsberg P. Mechanisms of T-cell activation by human T-cell lymphotropic virus type I. Micro. Mol. Biol. Rev. 63:1999;308-333
38. Miyatake S., Seiki M., Yoshida M., Arai K. T-cell activation signals and human T-cell leukemia virus type-I-encoded p40x protein activate the mouse granulocyte-macrophage colony-stimulating factor gene through a common DNA element. Mol. Cell Biol. 8:1988;5581-5587
39. Miyoshi I., Kubonishi I., Sumida M., Hiraki S., Tsubota T., Kimura I., Miyamoto K., Sato J. A novel T-cell line derived from adult T-cell leukemia. Gann. 71:1980;155-156
40. Colgin M.A., Nyborg J. The human T-cell leukemia virus type 1 oncoprotein tax inhibits the transcriptional activity of c-myb through competition for the CREB binding protein. J. Virol. 72:1998;9396-9399
41. Jin D.Y., Giordano V., Kibler K.V., Nakano H., Jeang K.T. Human T-cell leukemia virus type I Tax interacts directly with I B kinase. J. Biol. Chem. 274:1999;17402-17405
42. Low K.G., Dorner L.F., Fernando D.B., Grossman J., Jeang K.T., Comb M.J. Human T-cell leukemia virus type 1 Tax releases cell cycle arrest induced by p16INK4a. J. Virol. 71:1997;1956-1962
43. Ohtani K., Nakamua M., Saito S., Nagata K., Sugamura K., Hinuma Y. Electroporation: application to human lymphoid cell lines for stable introduction of a transactivator gene of human T-cell leukemia virus type I. Nucleic Acids Res. 17:1989;1589-1604
44. Van Orden K., Giebler H.A., Lemasson L., Gonzales M., Nyborg J.K. Binding of p53 to the KIX domain of CREB binding protein. J. Biol. Chem. 274:1999;26321-26328
45. Ashcroft M., Kubbutat M.H.G., Vousden K.H. Regulation of p53 function and stability by phosphorylation. Mol. Cell Biol. 19:1999;1751-1758
46. Bunz F., Hwang P.M., Torrance C., Waldman T., Zhang Y., Dillehay L., Williams J., Lengauer C., Kinzler K.W., Vogelstein B. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Invest. 104:1999;263-269
47. Mortenson M.M., Schlieman M.G., Virudalchalam S., Bold R.J. Overexpression of BCL-2 results in activation of the AKT/ NF-kB Cell survival pathway. J. Surg. Res. 114(2):2003;302